[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Nakamoto et al., 2000 - Google Patents

Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas

Nakamoto et al., 2000

View PDF @Full View
Document ID
11973643057266550329
Author
Nakamoto Y
Higashi T
Sakahara H
Tamaki N
Kogire M
Doi R
Hosotani R
Imamura M
Konishi J
Publication year
Publication venue
Cancer

External Links

Snippet

BACKGROUND Positron emission tomography (PET) using 18F‐fluoro‐2‐deoxy‐D‐glucose (FDG) has been used for the evaluation of various tumors, but accumulation in inflammatory lesions makes it a controversial modality. The aim of this study was to investigate the …
Continue reading at acsjournals.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0409Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414Particles, beads, capsules or spheres
    • A61K49/0423Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer

Similar Documents

Publication Publication Date Title
Nakamoto et al. Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas
Delbeke et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
Eubank et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer
Rusthoven et al. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor
Fuster et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures
Arnaud et al. Is 18F‐fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis?
Welin et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors
Tan et al. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy
Israel et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
Fueger et al. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin’s lymphoma
Pfluger et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT
Murakami et al. FDG-PET/CT in the diagnosis of recurrent breast cancer
Marner et al. Early postoperative 18F-FET PET/MRI for pediatric brain and spinal cord tumors
Ristau et al. Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer
Filippi et al. Recent advances in PET probes for hepatocellular carcinoma characterization
Izuishi et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer
Querellou et al. Prognostic value of fluorine‐18 fluorodeoxyglucose positron‐emission tomography imaging in patients with head and neck squamous cell carcinoma
Iagaru et al. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18] fluoro-D-glucose-PET and PET/CT
Zhao et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor
Liu et al. One-stop [18F] FDG and [68Ga] Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study
Watanabe et al. The usefulness of 18 F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)
Sohn et al. Is there an additive value of 18 F-FDG PET-CT to CT/MRI for detecting nodal metastasis in oropharyngeal squamous cell carcinoma patients with palpably negative neck?
Baiocchi et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results
Pu et al. The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review
Amorim et al. Performance of 18 F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer